Metronidazole

Metronidazole

Generic Name

Metronidazole

Mechanism

  • Metronidazole is a pro‑drug that is reduced in anaerobic organisms and select protozoa by nitroreductase enzymes.
  • Reduction generates radical nitro ions that damage microbial DNA strand breaks and inhibit macromolecule synthesis.
  • The drug is ineffective against bacteria that possess oxygen‑dependent metabolic pathways, explaining its specificity for anaerobes (e.g., *Bacteroides*, *Clostridium*, *Peptostreptococcus*) and protozoa (e.g., *Giardia*, *Trichomonas*, *Entamoeba*).

Pharmacokinetics

  • Absorption: Rapid and almost complete (≈ 96–98 %) when given orally or IV.
  • Distribution: Widely distributed; high concentrations in GI tract, uterus, placenta, and CNS. Penetration into cystic fluid and abscesses is modest.
  • Metabolism: Primarily glucuronidation in the liver; also undergoes conjugation in the intestine.
  • Elimination: Excreted unchanged in urine (≈ 85 %); half‑life 8–11 h.
  • Drug interactions: Inhibits CYP2C9/CYP2C19; decreases metabolism of warfarin, phenytoin, and sulfamethoxazole/trimethoprim – risk of toxicity.

Indications

  • Anaerobic bacterial infections: appendicitis, diverticulitis, intra‑abdominal abscesses, peritonitis.
  • Protozoal infections:
  • *Giardia lamblia* (asymptomatic or symptomatic intestinal disease)
  • *Trichomonas vaginalis* (vaginal trichomoniasis)
  • *Entamoeba histolytica* (amoebic dysentery and liver abscess)
  • Intra‑abdominal sepsis: used in combination with broad‑spectrum agents.
  • Dental infections & oral abscesses.

Contraindications

  • Contraindications:
  • Hypersensitivity to nitroimidazole class.
  • Severe hepatic impairment (due to hepatic glucuronidation).
  • Warnings:
  • Teratogenic and abortifacient; avoid during pregnancy.
  • Neurotoxicity: risk of peripheral neuropathy, cerebellar dysfunction, and seizures with prolonged high‑dose therapy.
  • Alcohol interaction: disulfiram‑like reaction (nausea, vomiting, flushing) – advise complete avoidance of alcohol.
  • Liver disease: dose adjustment may be required.

Dosing

IndicationAdult DoseRouteDuration
GI anaerobic infection500 mg PO/IV q8hPO or IV7–14 days (treat as per IDSA)
Giardiasis250 mg PO q12hPO5–7 days
Trichomoniasis2 g PO single dosePOSingle dose or 500 mg BID for 7 days
Amoebic dysentery500 mg PO q12hPO5–7 days
Pericarditis, abscess500 mg PO q8hPO10–14 days

*For children:* 15–20 mg/kg/day divided q8h, max 1 g/day.
IV infusion over 1–2 h to minimize headache and nausea.
• Adjust for renal dysfunction: >60 mL/min: no adjustment; 30–60 mL/min: reduce dose by 50 %; <30 mL/min: further dose reduction.

Adverse Effects

  • Common (≥1 %): nausea, vomiting, metallic taste, abdominal pain, headache, diarrhea.
  • Serious:
  • Peripheral neuropathy (tinnitus, numbness) – dose‑dependent.
  • Severe CNS effects: ataxia, seizures, myoclonic movements (especially with high doses or prolonged therapy).
  • Hypersensitivity rash, anaphylaxis.
  • Liver enzyme elevations (monitor LFTs).
  • Alcohol‑induced disulfiram reaction.

Monitoring

  • Liver Function Tests (LFTs): baseline and every 4–6 weeks for prolonged therapy.
  • Renal Function: baseline, then monthly if creatinine >1 mg/dL.
  • Neurologic status: at baseline and throughout therapy for signs of neuropathy or CNS toxicity.
  • Prothrombin Time/INR: if co‑administered with warfarin.
  • Pregnancy status: confirm trimester; discuss conception planning.

Clinical Pearls

  • Avoid Alcohol: Even brief exposure during treatment can precipitate an acute, painful reaction; counsel patients to abstain for at least 48 h after completing therapy.
  • Single‑dose Trichomoniasis Regimen: 2 g PO is highly efficacious and improves compliance compared to the 7‑day BID schedule.
  • Pericardial/Brain Abscesses: Metronidazole penetrates abscess cavities, making it the drug of choice for anaerobic coverage.
  • Pregnancy Category: C; use only when benefits outweigh risks; switch to clindamycin if possible.
  • Combination Therapy: When treating polymicrobial intra‑abdominal infection, pair Metronidazole with a β‑lactam/β‑lactamase inhibitor or carbapenem for optimal anaerobic coverage.
  • Dose Reduction in Elderly: Monitor for neurotoxicity; consider lower starting doses or extended‑interval dosing.

--
Key takeaways: Metronidazole’s unique ability to selectively target anaerobic bacteria and protozoa, combined with its excellent oral bioavailability, makes it indispensable for treating a broad spectrum of infections. However, careful attention to dosing, drug interactions, pregnancy precautions, and adverse effect monitoring is essential for safe, effective therapy.

Medical & AI Content Disclaimers
Medical Disclaimer: Medical definitions are provided for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

AI Content Disclaimer: Some definitions may be AI-generated and may contain inaccuracies. Always verify with authoritative medical references.

Scroll to Top